It occurs to me that there is going to come a point in time in the next several weeks where we will know for sure whether B can become a widely used treatment for patients with moderate to severe COVID19. If the Selectivity Index and human lung cell studies are any indication, B should be able to perform admirably. There are currently about 115K people hospitalized due to COVID in the U.S. alone with about 30K new hospitalizations per week.

This statement from the Nov 2nd PR suggests things will now move very quickly:

"Contract Research Organizations have been secured to expedite trial enrollment with many clinical sites expressing interest in participating in the study. The Company anticipates commencing the Brilacidin for COVID-19 clinical trial in 4Q2020."

Imagine if B works as well in humans as it did in the cells and we see those results in the very near future!